Adverum Biotechnologies Inc Cash Flow Conversion Efficiency
Adverum Biotechnologies Inc cash flow conversion efficiency. Based on the latest financial reports, Adverum Biotechnologies Inc (ADVM) has a cash flow conversion efficiency ratio of 0.505x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-28.11 Million) by net assets ($-55.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Adverum Biotechnologies Inc (2012–2024)
Cash flow conversion efficiency of Adverum Biotechnologies Inc from 2012 to 2024. This chart illustrates how Adverum Biotechnologies Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Adverum Biotechnologies Inc stock quote for real-time trading data and today's change.
Adverum Biotechnologies Inc Cash Flow Conversion Ratio Explained
Adverum Biotechnologies Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Adverum Biotechnologies Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adverum Biotechnologies Inc ranked by their cash flow conversion efficiency. Also see market cap of Adverum Biotechnologies Inc for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Virco Manufacturing Corporation
NASDAQ:VIRC
|
-0.091x |
|
Spheria Emerging Companies Ltd
AU:SEC
|
0.046x |
|
Ifishdeco PT
JK:IFSH
|
0.057x |
|
Tong Herr Resources Bhd
KLSE:5010
|
0.126x |
|
Laiqon AG
XETRA:LQAG
|
0.037x |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
-0.003x |
|
Orient Technologies Limited
NSE:ORIENTTECH
|
-0.009x |
|
Piscines Desjoyaux SA
PA:ALPDX
|
0.059x |
Annual Cash Flow Conversion Efficiency for Adverum Biotechnologies Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Adverum Biotechnologies Inc from 2012 to 2024. Review ADVM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $70.71 Million | $-92.46 Million | -1.308x | +3.31% |
| 2023-12-31 | $67.22 Million | $-90.90 Million | -1.352x | -127.09% |
| 2022-12-31 | $181.52 Million | $-108.09 Million | -0.595x | -74.61% |
| 2021-12-31 | $316.19 Million | $-107.83 Million | -0.341x | -86.82% |
| 2020-12-31 | $434.35 Million | $-79.29 Million | -0.183x | +35.04% |
| 2019-12-31 | $174.96 Million | $-49.17 Million | -0.281x | -4.77% |
| 2018-12-31 | $201.17 Million | $-53.96 Million | -0.268x | -8.69% |
| 2017-12-31 | $184.03 Million | $-45.42 Million | -0.247x | -38.70% |
| 2016-12-31 | $215.60 Million | $-38.37 Million | -0.178x | -27.20% |
| 2015-12-31 | $252.59 Million | $-35.34 Million | -0.140x | -270.27% |
| 2014-12-31 | $149.48 Million | $-5.65 Million | -0.038x | -100.38% |
| 2013-12-31 | $-218.00K | $-2.17 Million | 9.977x | +685.09% |
| 2012-12-31 | $-997.00K | $-1.27 Million | 1.271x | -- |
About Adverum Biotechnologies Inc
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec Ixo-vec, a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is … Read more